The size of the Latin America High Potency APIs market was valued at USD 2.56 billion in 2021. It is further estimated to be growing at a CAGR of 8.3% and value USD 3.81 billion by 2026.
High Potency Active Pharmaceutical Ingredients (HPAPI) are pharmacologically active substances and intermediates at concentrations below 150 micrograms per kilogram of body weight. They are highly selective; hence they can bind to specific receptors or enzymes, which can cause cancer, reproductive problems, and developmental disorders at low doses. Many new pharmaceutical drugs have these drugs, leading to the high growth of this market.
High Potency Active Pharmaceutical Ingredients gave rise to a new set of medicines to treat medical ailments, especially cancer. The mapping of the human genome gave the possibility of producing new cancer-treating drugs for different cancers and different patients. Since they are active even at low concentrations, they have to be prepared with great care. They can cause serious health issues to workers if proper care is not taken. Safety steps are to be taken to prevent the contamination of drugs with contaminants. So, it requires specialized equipment for handling HPAPI’s and managing air quality.
Some of the driving factors of Latin America High Potency Active Pharmaceutical Ingredients market are low prices, growing healthcare prices, rising government initiatives to increase the usage of generic medicines so that healthcare costs can be cut down, rising number of pharmaceutical manufacturers and patients.
This market's restraining agents are lack of skilled workers, stringent regulatory requirements, and the high price of equipment.
This research report on the Latin America HPAPI Market has been segmented and sub-segmented into the following categories:
By Type:
By Synthesis:
By Therapeutic Application:
By Country:
Geographically, this market is still in its initial stages in this region. Factors such as the growing incidence of cancer, increased funding into cancer research, and approval for new drugs' production are expected to amplify this market's growth in the region.
Noteworthy Companies dominating the Latin America High Potency Active Pharmaceutical Ingredients Market profiled in the report are Pfizer, Inc. (U.S.), Novartis International AG (Switzerland), Sanofi (France), F. Hoffmann-La Roche Ltd. (Switzerland), Eli Lilly and Company (U.S.), Bristol-Myers Squibb (U.S.), Boehringer Ingelheim (Germany), Teva Pharmaceutical Industries Ltd. (Israel), Merck & Co., Inc. (U.S.), AbbVie Inc. (U.S.), and Mylan Inc. (U.S.).
1.Introduction
1.1 Market Definition
1.2 Study Deliverables
1.3 Base Currency, Base Year and Forecast Periods
1.4 General Study Assumptions
2. Research Methodology
2.1 Introduction
2.2 Research Phases
2.2.1 Secondary Research
2.2.2 Primary Research
2.2.3 Econometric Modelling
2.2.4 Expert Validation
2.3 Analysis Design
2.4 Study Timeline
3. Overview
3.1 Executive Summary
3.2 Key Inferences
3.3 Epidemology
4. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)
4.1 Market Drivers
4.2 Market Restraints
4.3 Key Challenges
4.4 Current Opportunities in the Market
5. Market Segmentation
5.1 Type
5.1.1 Innovative HPAPI's
5.1.2 Generic HPAPI's
5.1.3 Y-o-Y Growth Analysis, By Type
5.1.4 Market Attractiveness Analysis, By Type
5.1.5 Market Share Analysis, By Type
5.2 Synthesis
5.2.1 Biotech HPAPI's
5.2.1.1 Biotech High- otency Active Pharmaceutical Ingredients Market, By Type
5.2.1.1.1 Innovative Biotech HPAPIs
5.2.1.1.2 Biosimilars
5.2.2 Synthetic HPAPI's
5.2.2.1 Synthetic High Potency Active Pharmaceutical Ingredients Market, By Type
5.2.2.1.1 Innovative Synthetic HPAPIs
5.2.2.1.2 Generic Synthetic HPAPIs
5.2.3 Y-o-Y Growth Analysis, By Synthesis
5.2.4 Market Attractiveness Analysis, By Synthesis
5.2.5 Market Share Analysis, By Synthesis
5.3 Therapeutic Application
5.3.1 Oncology
5.3.2 Glaucoma
5.3.3 Hormonal Balance
5.3.4 Other therapeutic applications
5.3.5 Y-o-Y Growth Analysis, By Therapeutic Application
5.3.6 Market Attractiveness Analysis, By Therapeutic Application
5.3.7 Market Share Analysis, By Therapeutic Application
5.4 Manufacturer
5.4.1 Captive Manufacturers
5.4.2 Merchant Manufacturers
5.4.2.1 Merchant HPAPI Manufacturers Market, By Type
5.4.2.1.1 Innovative Merchant HPAPI Manufacturers
5.4.2.1.2 Generic Merchant HPAPI Manufacturers
5.4.2.2 Merchant HPAPI Manufacturers Market, By Type of Synthesis
5.4.2.2.1 Synthetic HPAPIs
5.4.2.2.2 Biotech HPAPIs
5.4.3 Y-o-Y Growth Analysis, By Manufacturer
5.4.4 Market Attractiveness Analysis, By Manufacturer
5.4.5 Market Share Analysis, By Manufacturer
6. Geographical Analysis
6.1 Introduction
6.1.1 Regional Trends
6.1.2 Impact Analysis
6.1.3 Y-o-Y Growth Analysis
6.1.3.1 By Type
6.1.3.2 By Synthesis
6.1.3.3 By Therapeutic Application
6.1.3.4 By Manufacturer
6.1.4 Market Attractiveness Analysis
6.1.4.1 By Type
6.1.4.2 By Synthesis
6.1.4.3 By Therapeutic Application
6.1.4.4 By Manufacturer
6.1.5 Market Share Analysis
6.1.5.1 By Type
6.1.5.2 By Synthesis
6.1.5.3 By Therapeutic Application
6.1.5.4 By Manufacturer
6.2 Brazil
6.3 Mexico
6.4 Rest of Latin America
7.Strategic Analysis
7.1 PESTLE analysis
7.1.1 Political
7.1.2 Economic
7.1.3 Social
7.1.4 Technological
7.1.5 Legal
7.1.6 Environmental
7.2 Porter’s Five analysis
7.2.1 Bargaining Power of Suppliers
7.2.2 Bargaining Power of Consumers
7.2.3 Threat of New Entrants
7.2.4 Threat of Substitute Products and Services
7.2.5 Competitive Rivalry within the Industry
8.Market Leaders' Analysis
8.1 Pfizer Inc.
8.1.1 Overview
8.1.2 Product Analysis
8.1.3 Financial analysis
8.1.4 Recent Developments
8.1.5 SWOT analysis
8.1.6 Analyst View
8.2 Novartis International AG
8.3 Sanofi
8.4 F. Hoffmann-La Roche Ltd.
8.5 Eli Lilly and Company
8.6 Bristol-Myers Squibb
8.7 Boehringer Ingelheim
8.8 Teva Pharmaceutical Industries Ltd.
8.9 Merck & Co., Inc.
8.10 AbbVie Inc.
8.11 Mylan Inc.
9.Competitive Landscape
9.1 Market share analysis
9.2 Merger and Acquisition Analysis
9.3 Agreements, collaborations and Joint Ventures
9.4 New Product Launches
10.Market Outlook and Investment Opportunities
Appendix
a) List of Tables
b) List of Figures
Related Reports
Apr 2021
